FDA official announcements

Terns Pharmaceuticals' Weight-Loss Drug Shows 4.9% Reduction, Stock Surges

Sep 9, 2024, 11:33 AM

Terns Pharmaceuticals has announced positive Phase 1 clinical trial results for its once-daily oral GLP-1R agonist, TERN-601, aimed at treating obesity. The trial demonstrated a statistically significant mean weight loss of up to 5.5% over 28 days, with a placebo-adjusted weight loss of 4.9%. The study also reported an absence of treatment-related dose interruptions, reductions, or discontinuations, despite aggressive titration to high doses, and mostly mild AEs, suggesting improved tolerability with slower titration in future studies. Following the announcement, Terns Pharmaceuticals' stock surged, rising 10% in regular trading and 31% in premarket trading.